insights_auto
Outlook: 48.6% bullish·0.0% bearish
Go to analysischevron_right
GILD:NASDAQ
Gilead Sciences, Inc
156,19 USD
arrow_downward
-0,75%(-1,18) 1D
156,84 USD
arrow_upward
+0,42% (+0,65)bedtimeAfter hours
Closed: 16-окт., 16:00:02 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GILD...
Open
157,32 USD
High
157,58 USD
Low
155,62 USD
Mkt. cap
193,67 млд
Avg. vol.
5,79 млн
Volume
7,77 млн
Dividend
2,10%
Quarterly dividend
0,82 USD
Ex-dividend date
2026-ж., 15-сен.
52-wk high
160,51 USD
52-wk low
114,02 USD
EPS
-2,66 USD
Beta
0,32
Shares outstanding
1,24 млд
No. of employees
17 миң
Open
157,32 USD
High
157,58 USD
Low
155,62 USD
Mkt. cap
193,67 млд
Avg. vol.
5,79 млн
Volume
7,77 млн
Dividend
2,10%
Quarterly dividend
0,82 USD
Ex-dividend date
2026-ж., 15-сен.
52-wk high
160,51 USD
52-wk low
114,02 USD
EPS
-2,66 USD
Beta
0,32
Shares outstanding
1,24 млд
No. of employees
17 миң
News stories
From web sources and news partners
MarketBeat
·
3 саат мурун
Gilead Sciences, Inc. $GILD Stake Cut by TD Waterhouse Canada Inc.
Simply Wall Street
·
14 саат мурун
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
Investing.com Nigeria
·
16 саат мурун
Gilead chairman & CEO O’Day sells $2.2m in stock
Investing.com Nigeria
·
1 күн мурун
Gilead chief comm & corp aff officer sells $468,660 in GILD shares
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17 миң
Founded1987-ж., 22-июн.
HeadquartersФостер Сити, Калифорния, Америка Кошмо Штаттары
Sector-
Websitegilead.com